A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum- sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup ( GCIG)

被引：0
|
作者：
Pujade-Lauraine, E.
Mahner, S.
Kaern, J.
Gebski, V.
Heywood, M.
Vasey, P.
Reinthaller, A.
Vergote, I.
Pignata, S.
Ferrero, A.
机构：
[1] GINECO, Paris, France
[2] AGO OVAR, Hamburg, Germany
[3] NSGO, Oslo, Norway
[4] ANZGOG, Sydney, NSW, Australia
[5] NCIC, CTG, Vancouver, BC, Canada
[6] ANZGOG, Queensland, Australia
[7] AGO Austria, Vienna, Austria
[8] Eortc Data Ctr, Louvain, Belgium
[9] MITO, Naples, Italy
[10] MANGO, Turin, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer
    D D Gibbs
    L Pyle
    M Allen
    M Vaughan
    A Webb
    S R D Johnston
    M E Gore
    British Journal of Cancer, 2002, 86 : 1379 - 1384
  • [32] A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer
    Gibbs, DD
    Pyle, L
    Allen, M
    Vaughan, M
    Webb, A
    Johnston, SRD
    Gore, ME
    BRITISH JOURNAL OF CANCER, 2002, 86 (09) : 1379 - 1384
  • [33] Phase III randomized trial of maintenance pegylated liposomal doxorubicin (PLD) / carboplatin versus without in patients with advanced ovarian cancer: An Asian Gynecologic Oncology Group study.
    Lai, Chyong-Huey
    Vallikad, Elizabeth
    Lin, Hao
    Yang, Lan-Yan
    Ou, Yu-Che
    Chou, Hung-Hsueh
    Lin, Cheng-Tao
    Huang, Huei-Jean
    Huang, Kung-Gen
    Qiu, Jentai
    Hung, Yao-Ching
    Wu, Tzu-I
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial
    Pignata, Sandro
    Scambia, Giovanni
    Ferrandina, Gabriella
    Savarese, Antonella
    Sorio, Roberto
    Breda, Enrico
    Gebbia, Vittorio
    Musso, Pietro
    Frigerio, Luigi
    Del Medico, Pietro
    Lombardi, Alessandra Vernaglia
    Febbraro, Antonio
    Scollo, Paolo
    Ferro, Antonella
    Tamberi, Stefano
    Brandes, Alba
    Ravaioli, Alberto
    Valerio, Maria Rosaria
    Aitini, Enrico
    Natale, Donato
    Scaltriti, Laura
    Greggi, Stefano
    Pisano, Carmela
    Lorusso, Domenica
    Salutari, Vanda
    Legge, Francesco
    Di Maio, Massimo
    Morabito, Alessandro
    Gallo, Ciro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27) : 3628 - 3635
  • [35] A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLD) in progressive/recurrent ovarian cancer (OC)
    Ferrandina, G.
    Lorusso, D.
    Pignata, S.
    Breda, E.
    Savarese, A.
    Nardi, M.
    Scaltriti, L.
    Ludovisi, M.
    Scambia, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
    Gordon, AN
    Granai, CO
    Rose, PG
    Hainsworth, J
    Lopez, A
    Weissman, C
    Rosales, R
    Sharpington, T
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3093 - 3100
  • [37] Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive epithelial ovarian cancer (EOC)
    Kim, Kenneth H.
    Jelovac, Danijela
    Armstrong, Deborah Kay
    Weil, Susan
    Phillips, Martin
    Schwartz, Benjamin M.
    Estes, Jacob Michael
    Alvarez, Ronald David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC).
    Jelovac, D.
    Armstrong, D. K.
    Weil, S.
    Phillips, M.
    Schwartz, B. M.
    Estes, J. M.
    Alvarez, R. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Paclitaxel/carboplatin (TC) versus paclitaxel/carboplatin followed by topotecan (TOP) in first line treatment of advanced ovarian cancer.: Mature results of a gynecologic cancer interGroup (GCIG) phase III trial of the AGO OVAR and GINECO
    Pujade-Lauraine, E.
    Meden, H.
    Hardy-Bessard, A. C.
    Nitz, U.
    Mousseau, M.
    Blohmer, J. U.
    Flesch, M.
    Staehle, A.
    Mefti, F.
    Pfisterer, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 263 - 263
  • [40] CARBOPLATIN PLUS PACLITAXEL VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH OVARIAN CANCER: THE MITO-2 (MULTICENTRE ITALIAN TRIALS IN OVARIAN CANCER) RANDOMIZED PHASE III TRIAL
    Pignata, S.
    Scambia, G.
    Savarese, A.
    Sorio, R.
    Breda, E.
    Ferrandina, G.
    Murgia, V.
    Tamberi, S.
    Signoriello, S.
    Di Maio, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 304 - 304
12345